Amy
Paller
,
MS, MD
Northwestern University Feinberg Medical School
Chicago
,
Illinois
,
United States
Chair
IPC Board Member
ADDRESSING KEY GAPS IN DIAGNOSIS, TREATMENT, AND CARE FOR CHILDREN AND ADOLESCENTS
The IPC Pediatric Psoriasis Working Group is dedicated to improving the care and understanding of psoriasis in children and adolescents by addressing key gaps in diagnosis, treatment, and management. Pediatric psoriasis presents unique challenges, as many current tools and guidelines are adult-focused and may not meet the needs of younger patients. The group seeks to enhance clinical tools for diagnosis, severity assessment, and treatment response tracking, promote equitable access to care, support research on disease burden and patient- or proxy-reported outcomes, and foster global collaboration among experts. Through these efforts, the group aims to advance evidence-based care, improve outcomes, and better address the distinct needs of children and adolescents living with psoriasis.
View more resources on Pediatric Psoriasis.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.